HOME >> BIOLOGY >> NEWS
GM seed may be more widespread than we think

Strict segregation would keep crops free of genetically modified seed. But is it possible?

CONCERN over the accidental planting of genetically modified seed on several farms in Europe reached fever pitch last week. And now a company in the US has warned that the problem is probably commonplace.

"My guess is that it happens all the time," says Jeffrey Smith, vice president of marketing and communications at Genetic ID of Fairfield, Iowa. The company, which screens agricultural produce for GM material, found that more than half of 20 random samples of conventional seed taken from American distributors contained some GM seed.

The latest European furore began with the news that farmers throughout the continent have planted conventional oilseed rape containing traces of a sterile GM variety known as RT 73, which has not been approved for commercial planting in Europe. In Britain alone, 9000 hectares were sown with the adulterated seed in 1999, followed by 4700 hectares this spring.

In other European countries, including France and Sweden, ministers have considered ordering the destruction of affected crops. Opponents of GM crops accused governments of allowing the release of such crops before their environmental impact had been properly evaluated.

But this week, Genetic ID told New Scientist that such contamination might be just the tip of the iceberg. It says that in tests done last year, but not widely publicised, 12 out of 20 random American consignments of conventional maize seed contained detectable traces of GM maize. Two of these contained almost 1 per cent GM maize. Pioneer Hi-Bred, the largest supplier of both conventional and GM seeds in the US, acknowledged that low levels of mingling are inevitable. "Absolute zero purity is not achieved in any agricultural produce anywhere in the food chain," says Doyle Karr, a spokesman for the company.

Karr says Pioneer's conventional maize seeds exported
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
23-May-2000


Page: 1 2 3

Related biology news :

1. Circadian influence in plants more widespread than previously thought
2. Arsenic in New England wells more widespread than thought
3. First drug developed for widespread use against botulism
4. New technologies to battle little known, widespread cattle disease
5. Ethiopian fossil skull indicates Homo erectus was single, widespread species 1 million years ago
6. Hepatitis E virus infection may be widespread in rats
7. Rare deficit maps thinking circuitry
8. Muscles are smarter than you think
9. What are babies thinking before they start talking?
10. New book urges ecologists to think outside the helmet
11. UF researcher: Animals think in their own way, but unlike humans

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: seed may more widespread than think

(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: